Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-04-07 Capital/Financing Update
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing that Marvel Biosciences has secured financial and strategic investment support from 5 Horizons Ventures for its upcoming Phase I clinical trial. It focuses on the capital raising and financing arrangement (non-dilutive support covering 15% of CRO costs), fitting squarely under updates on company fundraising and financing activities. There is no indication of it being an earnings release, management discussion, regulatory filing, or other category. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-04-07 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that Marvel Biosciences has secured a financial and strategic investment from 5 Horizons Ventures to support its upcoming Phase I clinical trial. This is a capital raise/financing update rather than an earnings release, management change, or regulatory filing. Therefore the correct classification is a Capital/Financing Update (CAP).
2026-04-07 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing that Marvel Biosciences has secured $600,000 in non-dilutive funding from Alberta Innovates to support Phase I testing of its lead compound, as well as a grant from NRC IRAP. There are no financial results or earnings figures, no board or management changes, no dividends, and no references to regulatory filings or upcoming reports. Instead, it clearly represents a financing update (grant funding), fitting the definition for Capital/Financing Update (CAP).
2026-03-30 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by Marvel Biosciences Corp. announcing the granting of a patent by the Japan Patent Office for its lead therapeutic candidate, MB-204. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate regulatory announcement regarding business operations and intellectual property, it falls under the fallback category of Regulatory Filings (RNS).
2026-02-03 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory filing for 'Certification of Interim Filings' (Venture Issuer Basic Certificate). It is a legal certification signed by the CFO regarding the accuracy of interim financial reports and MD&A. Since it is a regulatory certification document rather than the financial report itself, and it does not fit into specific categories like '10-K' or 'IR', it is classified as a regulatory filing.
2025-12-18 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory filing known as a 'Certification of Interim Filings'. It is a mandatory compliance document signed by the CEO and CFO to certify the accuracy of interim financial reports. Since it is a regulatory compliance document that does not fit into the specific categories of financial reports (like 10-K or IR) or other specific corporate actions, it falls under the 'Regulatory Filings' category.
2025-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.